Technology remains at the heart of most growth opportunities. Artificial intelligence and the data centers needed to house ...

Investing at least part of the initial $1,000 in an artificial intelligence (AI) stock is a smart move. Despite impressive ...

Explore the unboxing and in-depth overview of the OCZ Vertex 4 Solid State Drive in our latest video. Discover the features and benefits of the Vertex 4, a cutting-edge SSD designed to enhance your ...

The stock's fall snapped a three-day winning streak.

Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals. If we consider the specifics of each trade, it is accurate to state that 9% of the investors ...

Highlights  Ghorashal ICD planned on 20 acres railway land Project aims to handle 1 lakh containers annually Two tender rounds fail to draw investor interest Political uncertainty, poor connectivity ...

Vertex Pharmaceuticals secured European approval for Alyftrek, reinforcing its dominance in cystic fibrosis treatment as ...

Journavx is the first truly new painkiller approved by the Food and Drug Administration in more than 20 years. But the drug is expensive, and many people can't get it yet.

This was the stock's second consecutive day of gains.

Vertex Pharmaceuticals Incorporated remains a top Buy with a strong cystic fibrosis franchise, innovative pipeline, and cell therapies. Click for my VRTX update.

PGIM Jennison Health Sciences Fund’s Q1 2025 letter highlights mixed sector returns, with Vertex Pharmaceuticals in focus.

The cryptocurrency market remained bullish on Tuesday, with Bitcoin above $108,000 after surging 1.33% in the last 24 hours.